Change in SEQENS’ shareholding structure
SEQENS is now stronger, more focused and positioned as one of the world’s leading players in pharmaceutical solutions and specialty ingredients 3 new…
Read moreOn Thursday, April 6, 2023, during the plenary session of the Franco-Chinese Business Council in Beijing and in the presence of the President of…
Read moreThe Seqens group has announced today that it has opened a state-of-the-art, 1,500 sqm R&D center in Devens, Mass., to serve as one…
Read moreSEQENS is committed, through its Drug Delivery Business Line, to accelerate its capabilities in Lipids & Polymers manufacturing on one of our cGMP Plant,…
Read moreFrom March 20 to 23, 2023, a delegation representing all the group’s pharmaceutical activities attended the DCAT week in New York. More than a…
Read moreBack in June 2020, Emmanuel Macron announced his will to restore France’s health sovereignty. Following this, Seqens has chosen to reshore a part of…
Read moreThis achievement reflects SEQENS strong commitment to reduce its environmental and carbon footprint in line with the Group ESG Program. SEQENS, an integrated…
Read moreFrom March 21 to 24, 2022, a delegation representing all of the group’s pharmaceutical activities took part in the DCAT event in New York.
Read moreInvestment Signals Major Commitment to U.S. Market and Builds on Merger with Contract Development and Manufacturing Organization Wavelength Pharmaceuticals. investment in Devens SEQENS,…
Read moreFor the International Women’s day, SEQENS highlights the career path of inspiring women working within the group. Meet Virginie Tarlet Roussillon Lab manager. What is…
Read moreFor the International Women’s day, SEQENS highlights the career path of inspiring women working within the group. Meet Aïna Queiroz, Head of innovation and scientific…
Read more